<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827472</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1521101</org_study_id>
    <nct_id>NCT04827472</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Single Dose, Dose-escalation Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety/tolerability and pharmacokinetic properties of DWJ1521 are evaluated after single&#xD;
      intravenous administration of DWJ1521 in healthy adults.&#xD;
&#xD;
      The safety/tolerability and pharmacokinetic properties of DWJ1521 single intravenous&#xD;
      administration and DWP14012 single oral administration in healthy adults are compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24h pH monitoring, the ratio of the time remaining above pH 4, 6 (time%)</measure>
    <time_frame>[Time Frame: [Time Frame: 0 - 72 hours after dosing]]</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part1(Cohort1) : DWJ1521 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1(Cohort2) : DWJ1521 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1(Cohort3) : DWJ1521 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1(Cohort4) : DWJ1521 Dmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 : DWJ1521 Xmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 : DWP14012 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>100ml</description>
    <arm_group_label>Part1(Cohort1) : DWJ1521 Amg</arm_group_label>
    <arm_group_label>Part1(Cohort2) : DWJ1521 Bmg</arm_group_label>
    <arm_group_label>Part1(Cohort3) : DWJ1521 Cmg</arm_group_label>
    <arm_group_label>Part1(Cohort4) : DWJ1521 Dmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1521</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Part1(Cohort1) : DWJ1521 Amg</arm_group_label>
    <arm_group_label>Part1(Cohort2) : DWJ1521 Bmg</arm_group_label>
    <arm_group_label>Part1(Cohort3) : DWJ1521 Cmg</arm_group_label>
    <arm_group_label>Part1(Cohort4) : DWJ1521 Dmg</arm_group_label>
    <arm_group_label>Part2 : DWJ1521 Xmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Tablet</intervention_name>
    <description>Single dose, Tablet</description>
    <arm_group_label>Part2 : DWP14012 Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults aged 19 to 50 years old at the time of screening test&#xD;
&#xD;
          2. Those who weigh 55.0 kg or more and 90.0 kg or less at the time of the screening test&#xD;
             and have a body mass index (BMI) of 18.0 or more and 28.0 or less â˜ž BMI(kg/m2) =&#xD;
             weight(kg) / {height(m)}2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant, liver, kidney, nervous system, immune system, respiratory&#xD;
             system, endocrine system, etc., or blood or tumor disease, cardiovascular disease,&#xD;
             mental disease (mood disorder, obsessive-compulsive disorder, etc.) or have a history&#xD;
             of character&#xD;
&#xD;
          2. Those with a history of gastrointestinal diseases (gastrointestinal ulcers, gastritis,&#xD;
             gastric cramps, gastroesophageal reflux disease, Crohn's disease, etc.) that may&#xD;
             affect the safety and pharmacokinetics evaluation of investigational drugs, and those&#xD;
             with a history of gastrointestinal surgery (However, simple appendic surgery and&#xD;
             hernia surgery are excluded)&#xD;
&#xD;
          3. Those who were tested positive for Helicobacter pylori&#xD;
&#xD;
          4. serologic test results (hepatitis B test, hepatitis C test, human immunodeficiency&#xD;
             virus (HIV) test) positive&#xD;
&#xD;
          5. Those whose blood AST and ALT exceeds 1.5 times the upper limit of the normal range in&#xD;
             screening tests including additional tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Injin Jang</last_name>
      <phone>82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

